Price target upside
Monte Rosa Therapeutics, Inc. Price Target: +83.9% vs Current Price
GLUE target gap is +83.9% from $15.50 to $28.50. As of 2026-08-16.
Direct answer
Monte Rosa Therapeutics, Inc.'s analyst target implies +83.9%.
The average target is $28.50 compared with a recorded current price of $15.50.
This percentage is calculated from the verified average target and recorded market price.
Forecast evidence checked August 16, 2026.
Get free Monte Rosa Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.50
- Average price target
- $28.50
- High price target
- $37.00
- Low price target
- $25.00
- Low target gap
- +61.3%
- Target upside
- +83.9%
- High target gap
- +138.7%
- Target range width
- 77.4%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- August 16, 2026
- Valid through
- August 23, 2026
Explore related company data
Read the frequently asked questions.
How much upside or downside does Monte Rosa Therapeutics, Inc.'s average target imply?
Monte Rosa Therapeutics, Inc.'s average target is $28.50 versus a recorded price of $15.50. The difference is +83.9%.
How far are Monte Rosa Therapeutics, Inc.'s low and high targets from the recorded price?
The low target implies +61.3%, while the high target implies +138.7%.
How many analysts are included in Monte Rosa Therapeutics, Inc.'s consensus?
The verified consensus includes 6 analysts.
How is Monte Rosa Therapeutics, Inc.'s target upside or downside calculated?
The average target of $28.50 is divided by the recorded price of $15.50, then one is subtracted to produce +83.9%. This does not guarantee a future return.
When was Monte Rosa Therapeutics, Inc.'s analyst forecast verified?
The data was verified on 2026-08-16. The dataset is valid through 2026-08-23.